TY  - JOUR
PY  - 2009//
TI  - Selective serotonin reuptake inhibitor (SSRI) drugs: more risks than benefits?
JO  - Journal of American physicians and surgeons
A1  - Kauffman, Joel M.
SP  - 7
EP  - 12
VL  - 14
IS  - 1
N2  - Anecdotal reports have suggested that selective serotonin reuptake inhibitors (SSRIs) may cause suicidal or violent behavior in some patients. Because of the publicity surrounding certain events, and the numerous lawsuits that have been filed, a review of benefits and risks is needed.    At most 30% of patients receive a benefit from SSRIs beyond the large placebo effect in certain mental conditions, especially depression, according to a recent meta-analysis of published trials. An equally recent meta-analysis of all SSRI trials submitted to the FDA showed a small benefit for the severely depressed patients only. Many early unpublished trials did not show any benefit.    Adverse effects are common, occurring in up to 75% of subjects. Severe adverse effects may be underreported. Metaanalyses of controlled trials did not include any actual suicides or murders, but only suicidality, some finding, in 1991 and 2007, no evidence even of suicidality. Other meta-analyses using many of the same trials found that suicidality doubled to 1 in 500 on SSRIs compared with placebo or non-SSRI antidepressants, but did not include any actual suicides or murders. The trial designs were devised by SSRI makers to prevent reports of suicides, by eliminating subjects with the slightest trace of suicidal tendencies. Retrospective studies by others showed actual suicides on SSRIs with a relative risk (RR) of 2–3 compared with non-SSRI antidepressants, with an increased incidence of 123/100,000.    Lower doses than the smallest available ones were found to maintain benefits in a majority of patients while reducing risks.    No causal connection between SSRIs and suicide and/or violence has been proved; neither has it been ruled out. Physicians need to be vigilant, and aware of legal precedents that may subject them to enhanced liability when prescribing these drugs.
LA  - en
SN  - 1543-4826
UR  - http://dx.doi.org/
ID  - ref1
ER  -